Intercomparison of S-Factor values calculated in Zubal voxelized phantom for eleven radionuclides commonly used in targeted prostate cancer therapy
In this study we aimed at comparing various radionuclides ordinarily used in targeted prostate cancer therapy, thereby evaluating S-Factor parameter in the prostate organs as well as in its surrounding healthy tissues, namely the urinary bladder and rectum. InterDosi code version 1.1 was used to est...
Gespeichert in:
Veröffentlicht in: | Australasian physical & engineering sciences in medicine 2022-12, Vol.45 (4), p.1251-1256 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | In this study we aimed at comparing various radionuclides ordinarily used in targeted prostate cancer therapy, thereby evaluating S-Factor parameter in the prostate organs as well as in its surrounding healthy tissues, namely the urinary bladder and rectum. InterDosi code version 1.1 was used to estimate S-Factor values in Zubal voxelized phantom for 11 radionuclides, namely
225
Ac,
21
At,
67
Cu,
125
I,
131
I,
212
Pb,
177
Lu,
223
Ra,
161
Tb,
227
Th and
90
Y. The prostate organ was considered the source of different ionizing radiation emitted by the radionuclides cited above. The results showed that among all studied alpha-emitting radionuclides,
225
Ac,
223
Ra and
227
Th provide equidistantly the highest self-irradiation S-Factors whereas,
211
At provides the lowest cross-irradiation S-Factors. On the other hand, considering only beta-emitting radionuclides, it is shown that
177
Lu and
90
Y induce respectively lowest and highest cross-absorption S-Factors on the surrounding healthy organs. We conclude that
177
Lu and
211
At are more adequate for prostate radionuclide therapy because they can relatively prevent surrounding organs from radiation toxicity and at the same time provide sufficient dose to treat the prostate tumor. |
---|---|
ISSN: | 2662-4729 0158-9938 2662-4737 1879-5447 |
DOI: | 10.1007/s13246-022-01191-7 |